keyword
MENU ▼
Read by QxMD icon Read
search

Avastin

keyword
https://www.readbyqxmd.com/read/28413496/clinical-observation-of-the-efficacy-of-bevacizumab-combined-with-argon-green-laser-in-treating-fundus-macular-edema
#1
Yi Shao, Yao Yu, Cheng Li, Chong-Gang Pei, Ping Tu, Yun Han, Gui-Ping Gao
We studied the clinical efficacy of Bevacizumab combined with argon green laser in treating fundus macular edema. From May 2009 to April 2013, 78 patients seeking treatment for macular edema in the First Affiliated Hospital of Nanchang University were enrolled in this study. Patients were randomly divided into two groups: i) The experimental group (n=39) and the control group (n=39). Patients in the experimental group were treated with Bevacizumab (Avastin(®)) combined with argon green laser, and those in the control group were treated exclusively with argon green laser...
April 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28409646/intravitreal-bevacizumab-alters-type-iv-collagenases-and-exacerbates-arrested-alveologenesis-in-the-neonatal-rat-lungs
#2
Arwin M Valencia, Charles L Cai, Jeffrey Tan, Thomas J Duggan, Gloria B Valencia, Jacob V Aranda, Kay D Beharry
Purpose/Aim: Intravitreal bevacizumab (Avastin) is an irreversible vascular endothelial growth factor (VEGF) inhibitor used off-label to treat severe retinopathy of prematurity in extremely low gestational age neonates. VEGF and matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) participate in lung maturation. We tested the hypothesis that intravitreal bevacizumab enters the systemic circulation and has long-lasting effects on lung MMPs. MATERIALS AND METHODS: Neonatal rats were exposed to: (1) hyperoxia (50% O2); (2) intermittent hypoxia (IH) (50% O2 with brief episodes of 12% O2); or (3) room air (RA) from birth (P0) to P14...
April 14, 2017: Experimental Lung Research
https://www.readbyqxmd.com/read/28357118/a-phase-1-study-comparing-the-proposed-biosimilar-bs-503a-with-bevacizumab-in-healthy-male-volunteers
#3
Naoyuki Tajima, Alberto Martinez, Fumiaki Kobayashi, Ling He, Peter Dewland
This is a randomized, double-blind, single-dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and tolerability of BS-503a, a proposed bevacizumab biosimilar. A total of 114 male healthy subjects were randomized (1:1) to receive a single 3 mg/kg intravenous dose of either BS-503a or bevacizumab (Avastin(®)). Pharmacokinetic (PK) blood samples were collected up to Day 78, and serum drug concentrations were measured using a validated enzyme-linked immunosorbent assay. Pharmacokinetic similarity was evaluated using area under the serum concentration-time curve from zero to infinity (AUC inf) as a primary PK parameter, and maximum serum concentration (Cmax) and area under the serum concentration-time curve from zero to the last measurable time (AUC last) as secondary PK parameters...
April 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28301412/large-silicone-droplets-after-intravitreal-bevacizumab-avastin
#4
Robert L Avery, Alessandro A Castellarin, Dilsher S Dhoot, Dante J Pieramici, Maʼan A Nasir, Nathan C Steinle, Logan P Avery, Gabriel M Gordon
PURPOSE: Despite its off-label status, intravitreal bevacizumab is the most commonly used intraocular anti-vascular endothelial growth factor agent. Regulation of compounding pharmacies has recently increased to make compounded pharmaceuticals safer. Despite these changes, a marked increase in symptomatic, large silicone oil droplets following intravitreal bevacizumab injections was noticed. METHODS: Retrospective chart review was performed. Within a single private practice, patients who were noted to have large or symptomatic silicone oil bubbles after an intravitreal injection were reviewed...
March 15, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28297041/fluorescein-angiography-versus-optical-coherence-tomography-angiography-in-macular-telangiectasia-type-i-treated-with-bevacizumab-therapy
#5
Nicolas A Yannuzzi, Ninel Z Gregori, Luiz Roisman, Nisha Gupta, Brian E Goldhagen, Raquel Goldhardt
This is a report of microvascular changes seen on fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) in a 47-year-old man with macular telangiectasia Type 1 (MacTel1) after a 7-year bevacizumab (Avastin; Genentech, South San Francisco, CA) treatment course. OCTA allowed for clear visualization of most telangiectasias and aneurysms in the deep capillary plexus, with only few microvascular dilatations in the superficial plexus. In addition, areas of capillary dropout in the superficial and deep vascular plexa located near telangiectasias were documented on OCTA...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28297035/short-term-effects-of-early-switching-to-ranibizumab-or-aflibercept-in-diabetic-macular-edema-cases-with-non-response-to-bevacizumab
#6
Mohammed Ashraf, Ahmed A R Souka, Hassan ElKayal
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28294622/tracking-antibody-distribution-with-near-infrared-fluorescent-dyes-impact-of-dye-structure-and-degree-of-labeling-on-plasma-clearance
#7
Cornelius Cilliers, Ian Nessler, Nikolas Christodolu, Greg M Thurber
Monoclonal antibodies labeled with near infrared (NIR) fluorophores have potential use in disease detection, intraoperative imaging, and pharmacokinetic characterization of therapeutic antibodies in both the preclinical and clinical setting. Recent work has shown conjugation of NIR fluorophores to antibodies can potentially alter antibody disposition at a sufficiently high degree of labeling (DoL); however, other reports show minimal impact after labeling with NIR fluorophores. In this work, we label two clinically approved antibodies Herceptin (trastuzumab) and Avastin (bevacizumab) with NIR dyes IRDye 800CW (800CW) or Alexa Fluor 680 (AF680), at 1...
March 15, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28256268/antiangiogenic-activity-of-a-bevacizumab-loaded-polyurethane-device-in-animal-neovascularization-models
#8
A E R Ferreira, B F M Castro, L C Vieira, G D Cassali, C M Souza, G O Fulgêncio, E Ayres, R L Oréfice, R Jorge, A Silva-Cunha, S L Fialho
PURPOSE: To evaluate the antiangiogenic activity of bevacizumab-loaded polyurethane using two animal models of neovascularization. METHODS: The percentage of blood vessels was evaluated in a chicken chorioallantoic membrane model (n=42) and in the rabbit cornea (n=24) with neovascularization induced by alkali injury. In each model, the animals were randomly divided into the groups treated with the bevacizumab-loaded polyurethane device, phosphate-buffered-saline (negative control) and bevacizumab commercial solution (positive control)...
March 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28238523/posterior-reversible-encephalopathy-syndrome-pres-with-sub-arachnoid-haemorrhage-after-bevacizumab-and-5-fu
#9
Jennifer Massey
PRES is a neurological syndrome characterised by reversible subcortical vasogenic brain oedema in patients with acute neurological signs and symptoms. It occurs in the context of fluctuations in blood pressure, renal failure, autoimmune disorders, eclamptic syndromes and with use of cytotoxic drugs. We present the case of a 60year old female with advanced bowel cancer who was admitted with seizures and sub-arachnoid haemorrhage, with radiographic features of PRES, shortly after receiving bevacizumab (Avastin), a VEGF-inhibitor...
February 23, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28194878/platelet-activated-serum-might-have-a-therapeutic-effect-on-damaged-articular-cartilage
#10
Munetaka Yokoyama, Masato Sato, Yoshiki Tani, Miyuki Yokoyama, Mami Kokubo, Masayuki Yamato, Teruo Okano, Joji Mochida
Platelet-activated serum (PAS) was collected from rabbits. This contains high concentrations of growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-BB, and transforming growth factor-beta (TGF-β). PAS was injected into the knee joints of Japanese White rabbits subjected to anterior cruciate ligament transection (ACL-T) to investigate its therapeutic effects on articular cartilage. The effect of Avastin (an anti-VEGF monoclonal antibody) on VEGF expression was also investigated...
February 14, 2017: Journal of Tissue Engineering and Regenerative Medicine
https://www.readbyqxmd.com/read/28193603/roche-asks-who-to-remove-avastin-from-essential-medicines-list
#11
Deborah Cohen
No abstract text is available yet for this article.
February 13, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28117563/patent-law-s-reproducibility-paradox
#12
Jacob S Sherkow
Clinical research faces a reproducibility crisis. Many recent clinical and preclinical studies appear to be irreproducible--their results cannot be verified by outside researchers. This is problematic for not only scientific reasons but also legal ones: patents grounded in irreproducible research appear to fail their constitutional bargain of property rights in exchange for working disclosures of inventions. The culprit is likely patent law’s doctrine of enablement. Although the doctrine requires patents to enable others to make and use their claimed inventions, current difficulties in applying the doctrine hamper or even actively dissuade reproducible data in patents...
January 2017: Duke Law Journal
https://www.readbyqxmd.com/read/28048647/tu-d-207b-07-radiomic-response-assessment-for-recurrent-glioblastoma-treated-with-bevacizumab-in-the-brain-trial
#13
P Grossmann, V Narayan, R Huang, H Aerts
PURPOSE: To develop radiomic biomarkers for non-invasive response assessment of Bevacizumab (Avastin; Genentech) treatment in recurrent glioblastoma multiforme (GBM). METHODS: We analyzed prospectively acquired data from the BRAIN trial. For 167 patients, we extracted 71 radiomic features each from normalized post-contrast T1-weighted and fluid attenuation inversion recovery (FLAIR) sequences at baseline (pretreatment), and at follow-ups of six and twelve weeks (post-treatment), respectively, where available...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28035003/a-quininib-analogue-and-cysteinyl-leukotriene-receptor-antagonist-inhibits-vascular-endothelial-growth-factor-vegf-independent-angiogenesis-and-exerts-an-additive-antiangiogenic-response-with-bevacizumab
#14
Clare T Butler, Alison L Reynolds, Miriam Tosetto, Eugene T Dillon, Patrick J Guiry, Gerard Cagney, Jacintha O'Sullivan, Breandán N Kennedy
Excess blood vessel growth contributes to the pathology of metastatic cancers and age-related retinopathies. Despite development of improved treatments, these conditions are associated with high economic costs and drug resistance. Bevacizumab (Avastin®), a monoclonal antibody against vascular endothelial growth factor (VEGF), is used clinically to treat certain types of metastatic cancers. Unfortunately, many patients do not respond or inevitably become resistant to bevacizumab, highlighting the need for more effective antiangiogenic drugs with novel mechanisms of action...
March 3, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27999187/targeting-the-pro-angiogenic-forms-of-vegf-or-inhibiting-their-expression-as-anti-cancer-strategies
#15
Mélanie Guyot, Caroline Hilmi, Damien Ambrosetti, Marco Merlano, Cristiana Lo Nigro, Jérôme Durivault, Renaud Grépin, Gilles Pagès
Tumor growth relies on oxygen and blood supply depending on neo-vascularization. This process is mediated by the Vascular Endothelial Growth Factor (VEGF) in many tumors. This paradigm has led to the development of specific therapeutic approaches targeting VEGF or its receptors. Despite their promising effects, these strategies have not improved overall survival of patients suffering from different cancers compared to standard therapies. We hypothesized that the existence of anti-angiogenic forms of VEGF VEGFxxxb which are still present in many tumors limit the therapeutic effects of the anti-VEGF antibodies bevacizumab/Avastin (BVZ)...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/27996119/bevacizumab-chemotherapy-for-management-of-pulmonary-and-laryngotracheal-papillomatosis-in-a-child
#16
Karen B Zur, Elizabeth Fox
Recurrent laryngeal papillomatosis (RRP) can be a devastating condition for a child to endure, and pulmonary involvement may have terminal consequences. Adjuvant therapies have been trialed and reported over the years; however, these chemotherapy options have not been successful. Bevacizumab (Avastin, Genetech Inc., South San Francisco, CA) is a vascular endothelial factor (VEGF) inhibitor that has shown promise in the management of papillomatosis. Most research has focused on intralesional injections of this antiangiogenic drug...
December 20, 2016: Laryngoscope
https://www.readbyqxmd.com/read/27972449/a-budget-impact-analysis-to-estimate-the-economic-consequences-of-introducing-the-combination-of-avastin-tarceva-for-the-treatment-of-first-line-epidermal-growth-factor-egfr-metastatic-non-small-cell-lung-cancer-nsclc
#17
P Orfanos, E J Wright, V C Munk
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27930983/sargassum-fusiforme-polysaccharides-inhibit-vegf-a-related-angiogenesis-and-proliferation-of-lung-cancer-in-vitro-and-in-vivo
#18
Huiling Chen, Ling Zhang, Xiange Long, Peifei Li, Shengcan Chen, Wei Kuang, Junming Guo
Sargassum fusiforme (Harv.) is a brown alga belonging to the Sargasaceae family. The Sargassum fusiforme polysaccharides (SFPS) have demonstrated good anti-tumor and immunomodulatory activity. However, the underlying mechanisms of its anti-tumorigenesis, especially the anti-angiogenic activity is yet to be established. In the present study, we attempted to determine the effects of SFPS on the human lung adenocarcinoma SPC-A-1 cells and its xenograft model. The results showed that SFPS provides a concentration-dependent inhibition of SPC-A-1 cell proliferation in in vitro and the tumor growth in in vivo studies...
January 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27928444/the-remote-effects-of-intravitreal-anti-vegf-therapy
#19
F Balta, M Merticariu, C Taban, G Neculau, A Merticariu, D Muresanu, D Badescu, V Jinga
Objective: To study the effects of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) therapy with Avastin for wet Age-Related Macular Degeneration (AMD) on Benign Prostatic Hyperplasia (BPH)-related symptoms. Methods: An exploratory trial was conducted from August 1, 2013 to February 1, 2014, that included 14 male patients previously diagnosed with BPH, who were aged between 59 and 69 years. The trial was performed in Bucharest and involved two medical institutions: the Clinical Hospital of Eye Emergencies and the "Prof...
October 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27896177/anti-vascular-endothelial-growth-factor-bevacizumab-therapy-reduces-hypertrophic-scar-formation-in-a-rabbit-ear-wounding-model
#20
Do Hoon Kwak, Tae Hui Bae, Woo Seob Kim, Han Koo Kim
BACKGROUND: Hypertrophic scarring is a pathological condition that occurs after trauma or surgery. Angiogenesis occurs more often with hypertrophic scarring than with normotrophic scarring. The regulation of angiogenesis is one of the key factors in hypertrophic scar management. Vascular endothelial growth factor (VEGF) is an essential factor in the angiogenetic response. This study investigated whether decreasing the level of VEGF is effective for treating hypertrophic scarring. METHODS: Ten 8-week-old female New Zealand white rabbits were included...
November 2016: Archives of Plastic Surgery
keyword
keyword
1771
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"